2021
DOI: 10.3390/cells10092418
|View full text |Cite
|
Sign up to set email alerts
|

The Saga of Endocrine FGFs

Abstract: Fibroblast growth factors (FGFs) are cell-signaling proteins with diverse functions in cell development, repair, and metabolism. The human FGF family consists of 22 structurally related members, which can be classified into three separate groups based on their action of mechanisms, namely: intracrine, paracrine/autocrine, and endocrine FGF subfamilies. FGF19, FGF21, and FGF23 belong to the hormone-like/endocrine FGF subfamily. These endocrine FGFs are mainly associated with the regulation of cell metabolic act… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
22
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 38 publications
(28 citation statements)
references
References 267 publications
(593 reference statements)
0
22
0
Order By: Relevance
“…FGF21 was first identified in 2000 principally in the liver (131) but was first described as a metabolic regulator in 2005 (132), involved in lipid metabolism, by decreasing adipose tissue lipolysis, increasing fatty acid oxidation and reducing hepatic lipids. Secondly, it is involved in glucose metabolism by decreasing plasma glucose, which mainly explain its higher circulating expression in patients with obesity and/or hepatic steatosis as a compensatory effect (14,133).…”
Section: Fgf21mentioning
confidence: 99%
See 1 more Smart Citation
“…FGF21 was first identified in 2000 principally in the liver (131) but was first described as a metabolic regulator in 2005 (132), involved in lipid metabolism, by decreasing adipose tissue lipolysis, increasing fatty acid oxidation and reducing hepatic lipids. Secondly, it is involved in glucose metabolism by decreasing plasma glucose, which mainly explain its higher circulating expression in patients with obesity and/or hepatic steatosis as a compensatory effect (14,133).…”
Section: Fgf21mentioning
confidence: 99%
“…Secondly, it is involved in glucose metabolism by decreasing plasma glucose, which mainly explain its higher circulating expression in patients with obesity and/or hepatic steatosis as a compensatory effect (14,133). In addition to its metabolic regulator role, FGF21 has been reported as a potential anti-diabetic therapy thanks to its ability to improve b-cell function and mass (132). This anti-diabetic role is explained by different mechanisms: decrease in plasma glucose and triglyceride levels which reduces b-cells' glucolipotoxicity and activate AKT signaling pathway which improves insulin sensitivity (14,134,135).…”
Section: Fgf21mentioning
confidence: 99%
“…FGFs contain a homologous core region of 120-130 amino acids arranged into 12 antiparallel β-strands, flanked by divergent amino-and carboxyl-termini. Sequence variation of the amino-and carboxyl-terminal tails usually accounts for the different biological functions of FGFs [3,4]. To date, twenty-two FGFs and four FGFRs have been identified in mammals.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, the scenario of possible biomarkers in chronic renal failure has been enriched by new players such as Fibroblast Growth Factor-23 (FGF-23) and Klotho. The progressive deterioration of renal function is characterized by a progressive reduction of Klotho protein and an increase of the FGF-23 levels [ 6 , 7 , 8 ].…”
Section: Introductionmentioning
confidence: 99%